All In Biotech

NDA 205065 · Biomarin Pharm

Kuvan

Sapropterin Dihydrochloride · Oral

Orphan

Last checked: Nov 20, 2026Latest source record: Aug 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Dec 19, 2013

Approved uses

1

Original approval plus efficacy supplements

Registered trials

64

12 Phase 3, 4 recruiting

FAERS reports

5,907

1,042 serious, 72 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 26, 2024.

KUVAN ® is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). KUVAN is to be used in conjunction with a Phe-restricted diet. KUVAN is a phenylalanine hydroxylase activator indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin‑ (BH4‑) responsive Phenylketonuria (PKU). KUVAN is to be used in conjunction with a Phe‑restricted diet. ( 1 )

Mechanism: KUVAN is a synthetic form of BH4, the cofactor for the enzyme phenylalanine hydroxylase (PAH). PAH hydroxylates Phe through an oxidative reaction to form tyrosine. In patients with PKU, PAH activity is absent or deficient. Treatment with BH4 can activate residual PAH enzyme activity, improve the normal oxidative metabolism of Phe, and decrease Phe levels in some patients.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • KUVAN · SAPROPTERIN DIHYDROCHLORIDE 100MG/PACKET · FOR SOLUTION, ORAL · Prescription · TE AB
  • KUVAN · SAPROPTERIN DIHYDROCHLORIDE 500MG/PACKET · FOR SOLUTION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sapropterin Dihydrochloride" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective358
  • headache358
  • therapy non-responder356
  • vomiting291
  • maternal exposure during pregnancy281
  • diarrhoea269
  • nausea218
  • amino acid level increased209
  • abdominal pain upper198
  • anxiety184
  • abdominal discomfort166
  • cough150

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200831
200999
2010194
201166
201257
201350
2014356
2015387
2016459
2017564
2018521
2019726
2020583
2021550
2022340
2023332
2024308
2025175
2026109

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kuvan (Sapropterin Dihydrochloride)

2024 spending

$3.5M

Beneficiaries

27

229 claims

Per beneficiary

$128,183

$126.92 per unit

View as table
YearSpending
2020$30,637,508
2021$19,517,146
2022$10,325,178
2023$6,802,220
2024$3,460,935

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 32 on PubMed

Sponsor: BioMarin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.